NKTRNektar Therapeutics

Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.

Nektar Therapeutics (NKTR) shares are in focus after the company reported second quarter 2026 results, with revenue of US$10.13 million and a net loss of US$40.62 million, alongside an earnings surprise relative to analyst expectations. See our latest analysis for Nektar Therapeutics. Nektar Therapeutics shares have eased in the very short term, with a 1-day share price return of 3.82% and a 7-day share price return of 4.52%. However, the stock still shows strong momentum with a year to date...

Nektar Therapeutics stock has delivered a very large gain over the past three years, yet the company now screens as expensive on broad valuation checks. After such a strong run, investors are facing a disconnect between past returns and what the current pricing suggests about future reward for risk. Nektar Therapeutics has returned almost 7x over the past three years, which raises the bar for any further upside from today's price. The launch of late stage trials for rezpegaldesleukin can...

Retail Sales Weaken in July

U.S. Stock Futures Mixed, Heads for a Winning Week.

Moby summary of Nektar Therapeutics's Q2 2026 earnings call

Nektar Therapeutics (NKTR) reports strong cash position and positive physician reception for Respeg, despite extended timelines for key data readouts.

Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting w

Nektar (NKTR) delivered earnings and revenue surprises of +40.29% and -6.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.